✦ LIBER ✦

157: Therapeutic Choices in Patients with Ph1 (+) Chronic Myelogenous Leukemia Living in Developing Countries in the Tyrosine Kinase Inhibitors (TKI) Era: Stem Cell Transplantation or TKI?

✍ Scribed by G.J. Ruiz-Arguelles; L.C. Tarin-Arzaga; M.L. Gonzalez-Carrillo; K.I. Gutierrez-Riveroll; R. Rangel-Malo; C.H. Gutierrez-Aguirre; O.G. Cantu-Rodriguez; D. Gomez-Almaguer; S. Giralt

Book ID: 116279985
Publisher: Elsevier Science
Year: 2008
Tongue: English
Weight: 50 KB
Volume: 14
Category: Article
ISSN: 1083-8791
DOI: 10.1016/j.bbmt.2007.12.166

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Therapeutic choices in patients with Ph-

Therapeutic choices in patients with Ph-positive CML living in Mexico in the tyrosine kinase inhibitor era: SCT or TKIs?

✍ Ruiz-Argüelles, G J; Tarin-Arzaga, L C; Gonzalez-Carrillo, M L; Gutierrez-Rivero 📂 Article 📅 2008 🏛 Nature Publishing Group 🌐 English ⚖ 142 KB

Prior treatment with the tyrosine kinase

Prior treatment with the tyrosine kinase inhibitors dasatinib and nilotinib allows stem cell transplantation (SCT) in a less advanced disease phase and does not increase SCT Toxicity in patients with chronic myelogenous leukemia and philadelphia positive acute lymphoblastic leukemia

✍ Shimoni, A; Leiba, M; Schleuning, M; Martineau, G; Renaud, M; Koren-Michowitz, M 📂 Article 📅 2008 🏛 Nature Publishing Group 🌐 English ⚖ 103 KB